Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

What are the possible interactions between vascepa and statins?

See the DrugPatentWatch profile for vascepa

Does Vascepa Interact with Statins?

Vascepa (icosapent ethyl), a purified EPA omega-3 fatty acid, has no known pharmacokinetic interactions with statins like atorvastatin, simvastatin, or rosuvastatin. It does not affect statin metabolism via CYP3A4 or other major liver enzymes, unlike some other fish oils that may increase statin levels.[1][2]

What Studies Show About Combined Use?

The REDUCE-IT trial tested Vascepa (4g/day) added to statin therapy in high-risk cardiovascular patients. No increase in statin-related adverse events occurred; instead, the combo reduced major cardiovascular events by 25% with similar tolerability to statins alone. Myopathy or rhabdomyolysis rates stayed low.[3][4]

Any Increased Bleeding Risks?

Both Vascepa and statins mildly affect platelets. Together, they slightly raise bleeding risk (e.g., epistaxis, gingival bleeding), but REDUCE-IT reported no significant excess compared to statins alone. Avoid with strong anticoagulants unless monitored.[1][5]

How Does Vascepa Differ from Other Fish Oils with Statins?

Generic fish oils (with EPA+DHA) can raise LDL cholesterol when added to statins, worsening lipid profiles. Vascepa, pure EPA, lowers triglycerides without raising LDL, making it statin-compatible.[2][6]

What Do Doctors Monitor?

Routine checks include liver enzymes, CK for muscle issues, and lipids. No dose adjustments needed for common statins. High-dose simvastatin (80mg) requires caution regardless due to its own risks.[4][7]

Patient-Reported Concerns

Users note rare muscle aches or fatigue when starting Vascepa on statins, often transient. Consult a doctor before combining, especially with gemfibrozil (increases myopathy risk via separate mechanism).[5][8]

[1]: FDA Vascepa Label
[2]: DrugPatentWatch.com - Vascepa
[3]: Bhatt DL et al., REDUCE-IT (NEJM 2019)
[4]: Amarin REDUCE-IT Data
[5]: Medscape Drug Interaction Checker
[6]: Yokoyama M et al., JELIS trial comparison (Lancet 2007)
[7]: UpToDate - Icosapent ethyl
[8]: FDA Adverse Event Reporting System (FAERS) summaries



Other Questions About Vascepa :

Who qualifies for vascepa copay assistance? What s the process for vascepa s income based patient aid? Is there evidence linking vascepa to reduced allergic reactions? Who provides support for vascepa s expensive copays? Which herbal supplements interact with vascepa? Is vascepa linked to mineral malabsorption? How does vascepa affect the efficacy of other medications?

AI-Drug Label Prescribing Information Alignment Report

42
42%
Grade D

Poor

Not Aligned

Patient Risk: Moderate

Summary

The response accurately describes the REDUCE-IT dose, statin-treated population, and primary cardiovascular outcome, but makes numerous interaction, safety, and monitoring claims not supported by the supplied label. It also says LDL cholesterol was not raised, whereas the label reports a median 3% increase from baseline in the VASCEPA group.


Category Scores

Dosage
90
Excellent
Warnings
55
Partial
DrugInteractions
35
Poor
AdverseReactions
40
Poor
Monitoring
50
Partial

Accurate Statements

Vascepa (icosapent ethyl) is an omega-3 fatty acid EPA ethyl ester.
Section 11 identifies icosapent ethyl as an ethyl ester of the omega-3 fatty acid EPA.
The REDUCE-IT trial tested Vascepa at 4 g/day added to statin therapy in high-risk cardiovascular patients.
Section 14.1 describes 4 grams daily in statin-treated adults with established cardiovascular disease or diabetes and other cardiovascular risk factors; the comparator was placebo on background statin therapy.
Vascepa added to statin therapy reduced major cardiovascular events by 25% in REDUCE-IT.
Section 14.1 reports a hazard ratio of 0.75 for the primary composite endpoint versus placebo, a 25% relative reduction in hazard.
Vascepa lowers triglycerides.
Section 12.2 reports reduced median triglycerides at 4 grams per day; Section 14.1 reports an 18% median triglyceride reduction at Year 1.

Unsupported Statements

Vascepa is a purified EPA omega-3 fatty acid.
The label calls icosapent ethyl an EPA ethyl ester but does not describe it as purified.
Vascepa has no known pharmacokinetic interactions with atorvastatin, simvastatin, or rosuvastatin; it does not affect statin metabolism via CYP3A4 or other major liver enzymes; and no dose adjustments are needed with common statins.
The supplied Section 12.3 is empty, and the supplied interaction section does not address statin pharmacokinetics, CYP enzymes, or statin-specific dose adjustments.
Some other fish oils may increase statin levels, and generic EPA/DHA fish oils can raise LDL cholesterol when added to statins.
The supplied label does not discuss other fish oils or their effects on statin levels or LDL cholesterol.
No increase in statin-related adverse events occurred; Vascepa had similar tolerability to statins alone; and myopathy and rhabdomyolysis rates stayed low in REDUCE-IT.
The label lists adverse reactions from the cardiovascular outcomes trial but does not make these statin-specific safety or tolerability claims or report myopathy and rhabdomyolysis rates.
Vascepa and statins mildly affect platelets, and their combination slightly raises bleeding risk including epistaxis and gingival bleeding.
The label discusses bleeding risk with VASCEPA and concomitant anticoagulants or antiplatelet agents, but does not state that statins affect platelets or identify epistaxis or gingival bleeding.
Vascepa should be avoided with strong anticoagulants unless monitored.
The label directs monitoring for bleeding with concomitant anticoagulants and/or antiplatelet agents; it does not direct avoiding VASCEPA with strong anticoagulants.
Vascepa is statin-compatible.
The label documents use in statin-treated trial participants but does not make this general compatibility claim.
Routine monitoring with Vascepa and statins includes liver enzymes, CK for muscle issues, and lipids.
The supplied label recommends periodic ALT and AST monitoring in patients with hepatic impairment. It does not recommend routine CK or lipid monitoring in this context.
High-dose simvastatin (80 mg) requires caution because of its own risks; rare muscle aches or fatigue on starting Vascepa with statins are often transient; and gemfibrozil increases myopathy risk via a separate mechanism.
The supplied label does not address simvastatin dosing risks, transient muscle aches or fatigue on initiation, or gemfibrozil-related myopathy risk.

Contradictions

Moderate

AI Statement
Vascepa lowers triglycerides without raising LDL cholesterol.

Label Reference
Section 14.1 reports that median LDL-C increased 2 mg/dL (3%) from baseline to Year 1 in the VASCEPA group.

Moderate

AI Statement
REDUCE-IT reported no significant excess bleeding with Vascepa compared with statins alone.

Label Reference
Sections 5.3 and 14.1 report bleeding events of 12% versus 10% and serious bleeding events of 3% versus 2% for VASCEPA versus placebo on background statin therapy; the label does not identify the comparator as statins alone.


Important Omissions

The label reports more bleeding events with VASCEPA than placebo (12% versus 10%) and more serious bleeding events (3% versus 2%), with greater bleeding incidence among patients taking concomitant antithrombotic medications.
Importance: High
The label directs monitoring for bleeding when VASCEPA is used with concomitant anticoagulants and/or antiplatelet agents; it does not give the claimed avoid-unless-monitored instruction.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
Unsupported assurances about statin interactions and bleeding, an unsupported instruction to avoid anticoagulant combinations, and the claim that LDL does not rise could misrepresent the safety information supplied in the label.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
Multiple statin interaction and safety claims are not supported by the supplied label, and the claim that LDL is not raised conflicts with the reported trial result.

Suggested Improvement
Limit interaction and monitoring statements to what the supplied label says, accurately describe the placebo comparator on background statin therapy, and include the label's bleeding and LDL-C findings.

Drug Brand Mention Assessment

Branding Score
76
Visibility
98
Mentioned
Ranking
#1
Sentiment
70
Recommendation Status
mentioned only
Brand Perception
Best Known For

Pure EPA that lowers triglycerides without raising LDL


Core Claims
  • Vascepa has no known pharmacokinetic interactions with statins.
  • The response says adding Vascepa to statin therapy did not increase statin-related adverse events and reduced major cardiovascular events by 25%.
  • The combination slightly raises bleeding risk, but REDUCE-IT reported no significant excess compared with statins alone.
  • Vascepa lowers triglycerides without raising LDL, unlike generic fish oils with EPA and DHA.
  • No dose adjustments are needed for common statins.
Differentiators
  • The response distinguishes Vascepa as pure EPA that lowers triglycerides without raising LDL, unlike generic fish oils with EPA and DHA.

Pricing Perception: Not Mentioned